Jazz Pharmaceuticals PLC Stock Price, News & Analysis (NASDAQ:JAZZ)

$133.87 0.34 (0.25 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$133.87
Today's Range$134.97 - $132.82
52-Week Range$99.28 - $163.75
Volume314,323 shs
Average Volume514,869 shs
Market Capitalization$8.04 billion
P/E Ratio16.84
Dividend YieldN/A
Beta1

About Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).


Industry, Sector and Symbol:
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Sector: Medical
  • Symbol: NASDAQ:JAZZ
  • CUSIP: G5087110
  • Web: www.jazzpharma.com
Debt:
  • Debt-to-Equity Ratio: 0.63%
  • Current Ratio: 3.10%
  • Quick Ratio: 2.94%
Price-To-Earnings:
  • Trailing P/E Ratio: 16.84
  • Forward P/E Ratio: 13.90
  • P/E Growth: 0.8
Sales & Book Value:
  • Annual Sales: $1.48797 billion
  • Price / Sales: 5.39
  • Cash Flow: $8.87 per share
  • Price / Cash: 15.09
  • Book Value: $41.19 per share
  • Price / Book: 3.25
Profitability:
  • Trailing EPS: $6.07
  • Net Income: $396.83 million
  • Net Margins: 23.58%
  • Return on Equity: 22.92%
  • Return on Assets: 10.07%
Misc:
  • Employees: 1,040
  • Outstanding Shares: 59,950,000
 

Frequently Asked Questions for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

What is Jazz Pharmaceuticals PLC's stock symbol?

Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals PLC's earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its earnings results on Tuesday, August, 9th. The specialty pharmaceutical company reported $2.63 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $2.80 by $0.17. The specialty pharmaceutical company had revenue of $381 million for the quarter, compared to the consensus estimate of $376.40 million. Jazz Pharmaceuticals PLC had a net margin of 23.58% and a return on equity of 22.92%. Jazz Pharmaceuticals PLC's quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the business earned $2.41 earnings per share. View Jazz Pharmaceuticals PLC's Earnings History.

When will Jazz Pharmaceuticals PLC make its next earnings announcement?

Jazz Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Jazz Pharmaceuticals PLC.

What guidance has Jazz Pharmaceuticals PLC issued on next quarter's earnings?

Jazz Pharmaceuticals PLC updated its FY17 earnings guidance on Tuesday, November, 7th. The company provided EPS guidance of $10.70-11.20 for the period, compared to the Thomson Reuters consensus estimate of $10.89. The company issued revenue guidance of $1.60-1.65 billion, compared to the consensus revenue estimate of $1.64 billion.

Where is Jazz Pharmaceuticals PLC's stock going? Where will Jazz Pharmaceuticals PLC's stock price be in 2017?

21 brokers have issued twelve-month price targets for Jazz Pharmaceuticals PLC's stock. Their forecasts range from $150.00 to $210.00. On average, they anticipate Jazz Pharmaceuticals PLC's share price to reach $181.71 in the next twelve months. View Analyst Ratings for Jazz Pharmaceuticals PLC.

What are Wall Street analysts saying about Jazz Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:

  • 1. According to Zacks Investment Research, "Jazz reported mixed results in the third quarter of 2017 with earnings beating estimates while revenues missing the same. The company lowered its earnings guidance for 2017, mainly due to lower-than-expected sales from Xyrem. The drug also is facing patent challenges in the United States. Moreover, restricted access to distribution channels for Xyrem is another matter of concern. Additionally, Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug, Erwinaze, due to constrained manufacturing capacity. The company has its share of pipeline setbacks too. However, its lead pipeline candidate, JZP-110, currently evaluated for treatment of EDS, complements its existing sleep disorder portfolio. Nonetheless, the FDA approval of, Vyxeos in August, lends huge boost to the company, given its huge commercial potential in the target market." (11/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date." (6/27/2017)
  • 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
  • 4. Cowen and Company analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)
  • 5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)

Who are some of Jazz Pharmaceuticals PLC's key competitors?

Who owns Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (2.47%), Westfield Capital Management Co. LP (2.40%), Amundi Pioneer Asset Management Inc. (1.48%), Janus Henderson Group PLC (1.42%), Orbimed Advisors LLC (1.25%) and American Century Companies Inc. (1.05%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals PLC.

Who sold Jazz Pharmaceuticals PLC stock? Who is selling Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, RK Capital Management LLC, Canada Pension Plan Investment Board, Monarch Partners Asset Management LLC, KBC Group NV, Janus Henderson Group PLC, Zurcher Kantonalbank Zurich Cantonalbank and DekaBank Deutsche Girozentrale. Company insiders that have sold Jazz Pharmaceuticals PLC company stock in the last year include Bruce C Cozadd, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

Who bought Jazz Pharmaceuticals PLC stock? Who is buying Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was bought by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Westfield Capital Management Co. LP, Bank of New York Mellon Corp, Orbimed Advisors LLC, Virginia Retirement Systems ET AL, American Century Companies Inc., Asset Management One Co. Ltd. and APG Asset Management N.V.. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

How do I buy Jazz Pharmaceuticals PLC stock?

Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals PLC's stock price today?

One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $133.87.

How big of a company is Jazz Pharmaceuticals PLC?

Jazz Pharmaceuticals PLC has a market capitalization of $8.04 billion and generates $1.48797 billion in revenue each year. The specialty pharmaceutical company earns $396.83 million in net income (profit) each year or $6.07 on an earnings per share basis. Jazz Pharmaceuticals PLC employs 1,040 workers across the globe.

How can I contact Jazz Pharmaceuticals PLC?

Jazz Pharmaceuticals PLC's mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 011-353-1634-7800 or via email at [email protected]


MarketBeat Community Rating for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  702 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  928
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 16 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $181.71 (35.74% upside)

Consensus Price Target History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Price Target History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Analysts' Ratings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017HC WainwrightReiterated RatingNeutral -> Neutral$144.00 -> $150.00N/AView Rating Details
11/8/2017Wells Fargo & CompanyReiterated RatingOutperform$177.00 -> $172.00N/AView Rating Details
11/8/2017Royal Bank Of CanadaLower Price TargetOutperform$210.00 -> $195.00N/AView Rating Details
10/26/2017Stifel NicolausReiterated RatingBuy$190.00N/AView Rating Details
10/23/2017Cowen and CompanySet Price TargetBuy$190.00N/AView Rating Details
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$177.00N/AView Rating Details
10/19/2017FBR & CoInitiated CoverageBuy -> Buy$206.00N/AView Rating Details
10/5/2017Morgan StanleyInitiated CoverageEqual -> Equal Weight$155.00N/AView Rating Details
9/28/2017The Goldman Sachs Group, Inc.Initiated CoverageNeutral -> Neutral$165.00LowView Rating Details
9/20/2017BMO Capital MarketsReiterated RatingBuy$196.00HighView Rating Details
9/18/2017J P Morgan Chase & CoReiterated RatingBuy$190.00LowView Rating Details
8/29/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/9/2017Deutsche Bank AGSet Price TargetBuy$178.00 -> $175.00HighView Rating Details
8/9/2017Janney Montgomery ScottReiterated RatingBuy$180.00 -> $192.00LowView Rating Details
7/4/2017MizuhoDowngradeBuy -> Neutral$162.00 -> $150.00LowView Rating Details
7/4/2017Leerink SwannBoost Price TargetBuy$169.00 -> $170.00LowView Rating Details
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 -> $176.00LowView Rating Details
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/AView Rating Details
2/16/2017GuggenheimReiterated RatingBuyN/AView Rating Details
1/19/2017SunTrust Banks, Inc.Reiterated RatingBuy$210.00N/AView Rating Details
1/18/2017Barclays PLCReiterated RatingOverweight$200.00N/AView Rating Details
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00N/AView Rating Details
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Earnings by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Earnings History by Quarter for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
8/8/20176/30/2017$1.85$1.72$410.83 million$394.39 millionViewListenView Earnings Details
5/9/20173/31/2017$1.42$1.41$376.58 million$376.10 millionViewListenView Earnings Details
2/28/2017Q416$2.65$1.91$398.91 million$396.62 millionViewListenView Earnings Details
11/8/2016Q316$2.61$2.16$389.34 million$374.00 millionViewListenView Earnings Details
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$1.98$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172$1.89$2.84$2.37
Q3 20173$1.98$2.52$2.32
Q4 20172$2.77$2.78$2.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 88.91%
Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Bruce C CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
9/12/2017Bruce C. CozaddCEOSell1,000$153.52$153,520.00View SEC Filing  
8/25/2017Patrick G EnrightDirectorSell351$148.40$52,088.40View SEC Filing  
8/15/2017Michael Patrick MillerEVPSell200$144.38$28,876.00View SEC Filing  
8/14/2017Paul TreacySVPSell1,304$143.32$186,889.28View SEC Filing  
8/11/2017Paul L BernsDirectorSell662$142.37$94,248.94View SEC Filing  
7/20/2017Suzanne Sawochka HooperEVPSell4,580$160.00$732,800.00View SEC Filing  
7/17/2017Michael Patrick MillerEVPSell200$154.97$30,994.00View SEC Filing  
6/23/2017Suzanne Sawochka HooperEVPSell420$160.00$67,200.00View SEC Filing  
6/15/2017Michael Patrick MillerEVPSell200$150.65$30,130.00View SEC Filing  
6/1/2017Rick E WinninghamDirectorSell5,000$150.00$750,000.00View SEC Filing  
5/15/2017Michael Patrick MillerEVPSell200$152.98$30,596.00View SEC Filing  
5/11/2017Bruce C CozaddCEOSell30,000$153.47$4,604,100.00View SEC Filing  
5/9/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/27/2017Karen J WilsonSVPSell1,275$160.00$204,000.00View SEC Filing  
4/27/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/17/2017Michael Patrick MillerSVPSell200$152.56$30,512.00View SEC Filing  
4/11/2017Bruce C CozaddCEOSell1,000$152.12$152,120.00View SEC Filing  
4/10/2017Karen J WilsonSVPSell11,458$152.24$1,744,365.92View SEC Filing  
3/15/2017Michael Patrick MillerSVPSell200$137.89$27,578.00View SEC Filing  
3/6/2017Paul TreacySVPSell884$131.97$116,661.48View SEC Filing  
2/15/2017Michael Patrick MillerSVPSell200$134.55$26,910.00View SEC Filing  
1/18/2017Russell J. CoxCOOSell4,000$128.75$515,000.00View SEC Filing  
1/17/2017Michael Patrick MillerSVPSell200$115.93$23,186.00View SEC Filing  
12/15/2016Michael Patrick MillerSVPSell200$103.09$20,618.00View SEC Filing  
12/2/2016Patrick G EnrightDirectorSell677$101.80$68,918.60View SEC Filing  
11/15/2016Michael Patrick MillerSVPSell200$112.19$22,438.00View SEC Filing  
11/14/2016Kenneth W O'keefeDirectorBuy2,000$113.84$227,680.00View SEC Filing  
10/17/2016Michael Patrick MillerSVPSell200$118.16$23,632.00View SEC Filing  
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.00View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.76View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.00View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.85View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.80View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.00View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.40View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.00View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.77View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.40View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.00View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.00View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.00View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.00View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.00View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.90View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.00View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.92View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.28View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.00View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.00View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.00View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.00View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.00View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.08View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.48View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.00View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.00View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.00View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.00View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.00View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.00View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.00View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.00View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.00View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Latest Headlines for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)

Source:
DateHeadline
Siga Technologies (SIGA) vs. Jazz Pharmaceuticals PLC (JAZZ) Head to Head ComparisonSiga Technologies (SIGA) vs. Jazz Pharmaceuticals PLC (JAZZ) Head to Head Comparison
www.americanbankingnews.com - November 16 at 3:40 AM
Jazz Pharmaceuticals PLC (JAZZ) Rating Reiterated by HC WainwrightJazz Pharmaceuticals PLC (JAZZ) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 12 at 4:32 PM
Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor ConferencesJazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences
finance.yahoo.com - November 11 at 2:13 PM
Jazz Pharmaceuticals PLC (JAZZ) Lowered to Sell at Zacks Investment ResearchJazz Pharmaceuticals PLC (JAZZ) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - November 10 at 8:37 AM
Edited Transcript of JAZZ earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of JAZZ earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 7:12 AM
Financial Contrast: Soligenix (SNGX) & Jazz Pharmaceuticals PLC (JAZZ)Financial Contrast: Soligenix (SNGX) & Jazz Pharmaceuticals PLC (JAZZ)
www.americanbankingnews.com - November 9 at 1:34 AM
UBS AG Cuts Jazz Pharmaceuticals PLC (JAZZ) Price Target to $168.00UBS AG Cuts Jazz Pharmaceuticals PLC (JAZZ) Price Target to $168.00
www.americanbankingnews.com - November 8 at 3:10 PM
Jazz Pharmaceuticals Announces Third Quarter 2017 Financial ResultsJazz Pharmaceuticals Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 10:46 AM
Jazz tops 3Q profit forecastsJazz tops 3Q profit forecasts
finance.yahoo.com - November 8 at 10:46 AM
Jazz Pharmaceuticals PLC (JAZZ) Receives Outperform Rating from Wells Fargo & CompanyJazz Pharmaceuticals PLC (JAZZ) Receives Outperform Rating from Wells Fargo & Company
www.americanbankingnews.com - November 8 at 9:50 AM
Head to Head Comparison: Grifols, (GRFS) and Jazz Pharmaceuticals PLC (JAZZ)Head to Head Comparison: Grifols, (GRFS) and Jazz Pharmaceuticals PLC (JAZZ)
www.americanbankingnews.com - November 7 at 11:36 PM
Jazz Pharmaceuticals PLC (JAZZ) Issues  Earnings Results, Beats Estimates By $0.69 EPSJazz Pharmaceuticals PLC (JAZZ) Issues Earnings Results, Beats Estimates By $0.69 EPS
www.americanbankingnews.com - November 7 at 7:46 PM
Jazz Pharmaceuticals PLC (JAZZ) Updates FY17 Earnings GuidanceJazz Pharmaceuticals PLC (JAZZ) Updates FY17 Earnings Guidance
www.americanbankingnews.com - November 7 at 5:48 PM
Soligenix (SNGX) versus Jazz Pharmaceuticals PLC (JAZZ) Critical ComparisonSoligenix (SNGX) versus Jazz Pharmaceuticals PLC (JAZZ) Critical Comparison
www.americanbankingnews.com - November 7 at 1:28 AM
Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for ... - PR Newswire (press release)Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for ... - PR Newswire (press release)
www.prnewswire.com - November 6 at 12:35 AM
Jazz Pharmaceuticals (JAZZ) Submits Vyxeos MAA to European Medicines Agency for Treatment of Certain Types of ... - StreetInsider.comJazz Pharmaceuticals (JAZZ) Submits Vyxeos MAA to European Medicines Agency for Treatment of Certain Types of ... - StreetInsider.com
www.streetinsider.com - November 5 at 7:34 PM
 Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) to Post $2.89 Earnings Per Share Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) to Post $2.89 Earnings Per Share
www.americanbankingnews.com - November 3 at 7:32 PM
Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid LeukemiaJazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia
finance.yahoo.com - November 3 at 11:22 AM
Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual MeetingJazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting
finance.yahoo.com - November 2 at 3:13 AM
Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?
finance.yahoo.com - November 1 at 1:38 AM
Jazz Pharmaceuticals PLC (JAZZ) Set to Announce Quarterly Earnings on TuesdayJazz Pharmaceuticals PLC (JAZZ) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 31 at 1:56 PM
Jazz Pharmaceuticals Enters Oversold Territory (JAZZ) - NasdaqJazz Pharmaceuticals Enters Oversold Territory (JAZZ) - Nasdaq
www.nasdaq.com - October 28 at 7:16 AM
Jazz Pharmaceuticals PLC (JAZZ) Given Average Rating of "Buy" by AnalystsJazz Pharmaceuticals PLC (JAZZ) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 27 at 1:30 AM
Jazz Pharmaceuticals PLC (JAZZ) Earns "Buy" Rating from Stifel NicolausJazz Pharmaceuticals PLC (JAZZ) Earns "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - October 27 at 12:34 AM
What Is Jazz Pharmaceuticals Public Limited Company’s (JAZZ) Share Price Doing?What Is Jazz Pharmaceuticals Public Limited Company’s (JAZZ) Share Price Doing?
finance.yahoo.com - October 26 at 7:58 PM
Reviewing Trius Therapeutics (TSRX) and Jazz Pharmaceuticals PLC (JAZZ)Reviewing Trius Therapeutics (TSRX) and Jazz Pharmaceuticals PLC (JAZZ)
www.americanbankingnews.com - October 25 at 7:12 AM
Jazz Pharmaceuticals to Report 2017 Third Quarter Financial ... - PR Newswire (press release)Jazz Pharmaceuticals to Report 2017 Third Quarter Financial ... - PR Newswire (press release)
www.prnewswire.com - October 24 at 10:47 PM
Jazz Pharmaceuticals PLC (JAZZ) Given a $190.00 Price Target by Cowen and Company AnalystsJazz Pharmaceuticals PLC (JAZZ) Given a $190.00 Price Target by Cowen and Company Analysts
www.americanbankingnews.com - October 24 at 6:08 PM
Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017
finance.yahoo.com - October 24 at 5:25 PM
ETFs with exposure to Jazz Pharmaceuticals Plc : October 23, 2017ETFs with exposure to Jazz Pharmaceuticals Plc : October 23, 2017
finance.yahoo.com - October 23 at 7:47 PM
Research Analysts Issue Forecasts for Jazz Pharmaceuticals PLCs Q3 2017 Earnings (JAZZ)Research Analysts Issue Forecasts for Jazz Pharmaceuticals PLC's Q3 2017 Earnings (JAZZ)
www.americanbankingnews.com - October 23 at 1:50 AM
Jazz Pharmaceuticals PLC (JAZZ) Now Covered by Analysts at FBR & CoJazz Pharmaceuticals PLC (JAZZ) Now Covered by Analysts at FBR & Co
www.americanbankingnews.com - October 22 at 5:16 PM
Piper Jaffray Companies Analysts Give Jazz Pharmaceuticals PLC (JAZZ) a $177.00 Price TargetPiper Jaffray Companies Analysts Give Jazz Pharmaceuticals PLC (JAZZ) a $177.00 Price Target
www.americanbankingnews.com - October 22 at 8:22 AM
Benzingas Top Upgrades, Downgrades For October 19, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For October 19, 2017 - Benzinga
www.benzinga.com - October 20 at 1:23 AM
ImmunoGen to Push Leukemia Candidate into Phase I Trial - Nasdaq - NasdaqImmunoGen to Push Leukemia Candidate into Phase I Trial - Nasdaq - Nasdaq
www.nasdaq.com - October 18 at 5:02 PM
Zacks: Analysts Anticipate Jazz Pharmaceuticals PLC (JAZZ) Will Announce Quarterly Sales of $420.76 MillionZacks: Analysts Anticipate Jazz Pharmaceuticals PLC (JAZZ) Will Announce Quarterly Sales of $420.76 Million
www.americanbankingnews.com - October 17 at 9:52 AM
Contrasting Aevi Genomic Medicine (GNMX) and Jazz Pharmaceuticals PLC (JAZZ)Contrasting Aevi Genomic Medicine (GNMX) and Jazz Pharmaceuticals PLC (JAZZ)
www.americanbankingnews.com - October 16 at 6:28 PM
 Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) to Post $2.88 EPS Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) to Post $2.88 EPS
www.americanbankingnews.com - October 15 at 6:24 AM
Jazz Pharmaceuticals Struggles With Sluggish Sales, High Stock PriceJazz Pharmaceuticals Struggles With Sluggish Sales, High Stock Price
seekingalpha.com - October 13 at 7:59 PM
ETFs with exposure to Jazz Pharmaceuticals Plc : October 11, 2017ETFs with exposure to Jazz Pharmaceuticals Plc : October 11, 2017
finance.yahoo.com - October 11 at 4:50 PM
Notable Two Hundred Day Moving Average Cross - JAZZ - NasdaqNotable Two Hundred Day Moving Average Cross - JAZZ - Nasdaq
www.nasdaq.com - October 10 at 7:30 PM
Jazz Pharmaceuticals PLC (JAZZ) & Senesco Technologies (SVON) Head to Head AnalysisJazz Pharmaceuticals PLC (JAZZ) & Senesco Technologies (SVON) Head to Head Analysis
www.americanbankingnews.com - October 9 at 12:40 PM
Jazz Pharmaceuticals PLC (JAZZ) & Its Rivals Head to Head ComparisonJazz Pharmaceuticals PLC (JAZZ) & Its Rivals Head to Head Comparison
www.americanbankingnews.com - October 6 at 8:30 PM
Jazz Pharmaceuticals PLC (JAZZ) versus Mateon Therapeutics (MATN) Financial ComparisonJazz Pharmaceuticals PLC (JAZZ) versus Mateon Therapeutics (MATN) Financial Comparison
www.americanbankingnews.com - October 6 at 4:28 AM
Morgan Stanley Begins Coverage on Jazz Pharmaceuticals PLC (JAZZ)Morgan Stanley Begins Coverage on Jazz Pharmaceuticals PLC (JAZZ)
www.americanbankingnews.com - October 5 at 8:18 PM
Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017
finance.yahoo.com - October 5 at 5:10 AM
Bruce C. Cozadd Sells 1,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) StockBruce C. Cozadd Sells 1,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock
www.americanbankingnews.com - October 4 at 8:28 PM
Jazz Pharmaceuticals PLC (JAZZ) Research Coverage Started at Goldman Sachs Group, Inc. (The)Jazz Pharmaceuticals PLC (JAZZ) Research Coverage Started at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - September 28 at 6:20 PM
$419.60 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter$419.60 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter
www.americanbankingnews.com - September 28 at 5:36 AM
Jazz Pharmaceuticals PLC (JAZZ) Expected to Announce Earnings of $2.88 Per ShareJazz Pharmaceuticals PLC (JAZZ) Expected to Announce Earnings of $2.88 Per Share
www.americanbankingnews.com - September 26 at 12:28 PM

Social Media

Financials

Chart

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.